Balyasny Asset Management
TSHA icon

Balyasny Asset Management’s Taysha Gene Therapies TSHA Stock Holding History

Balyasny Asset Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$371K Buy
83,019
+40,949
+97% +$190K ﹤0.01% 2482
2025
Q4 		$231K Buy
+42,070
New +$204K ﹤0.01% 2831
2024
Q2 		– Sell
-188,698
Closed -$542K – 3121
2024
Q1 		$542K Buy
+188,698
New +$393K ﹤0.01% 2020

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management's TSHA Position: Q1 2026 in Review

Balyasny Asset Management increased its Taysha Gene Therapies (TSHA) stake by 97% in Q1 2026, buying an estimated $190K and bringing the position to 83,019 shares worth $371K. The position accounts for ﹤0.01% of the portfolio, ranked #2482.

Balyasny Asset Management first reported a position in TSHA in Q1 2024 and has held it in 3 quarters since. The position peaked at $542K in Q1 2024. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Balyasny Asset Management held 83,019 shares of Taysha Gene Therapies worth $371K as of Q1 2026.
  • Balyasny Asset Management bought 40,949 Taysha Gene Therapies shares in Q1 2026, an estimated $190K.
  • Taysha Gene Therapies made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2482 holding.
  • Balyasny Asset Management first reported a position in Taysha Gene Therapies in Q1 2024 and has held it in 3 quarters since.
  • Balyasny Asset Management's Taysha Gene Therapies position peaked at $542K in Q1 2024.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.